Last Update

This profile was last updated on .

Is this you? Claim your profile.

Wrong Patrick Zarrinkar?

Dr. Patrick P. Zarrinkar

Head of Molecular Biology and Technology Development

Daiichi Sankyo , Inc.

Direct Phone: (858) ***-****       

Email: p***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Daiichi Sankyo , Inc.

Two Hilton Court

Parsippany, New Jersey 07054

United States

Company Description

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuti ... more

Find other employees at this company (3,788)

Background Information

Employment History

Head of Molecular Biology and Technology Development

Ambit Biosciences Corporation

Senior Director, Technology Development and Alliance Management

Ambit Biosciences Corporation

Vice President, Technology Development and Alliance Management

Ambit Biosciences Corporation

Staff Scientist

Genomics Institute of the Novartis Research Foundation

Education

Ph.D.

Massachusetts Institute of Technology

Web References (11 Total References)


Ambit Biosciences » About Ambit » Management Team

www.ambitbio.com [cached]

Patrick P. Zarrinkar, Ph.D. Vice President, Technology Development & Alliance Management

...
Patrick P. Zarrinkar, Ph.D.
Vice President, Technology Development & Alliance Management
Patrick P. Zarrinkar brings a deep understanding of genomics and high throughput screening to Ambit. Prior to joining Ambit in 2000, he was a Staff Scientist at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, where he worked in collaboration with Affymetrix, Inc. to develop high throughput methods for global gene expression profiling. Zarrinkar received his Ph.D. from Massachusetts Institute of Technology and conducted postdoctoral research in the lab of Professor Bruce Sullenger at Duke University Medical Center.


Earlier that morning, at 7:45 and ...

www.coldchainpharma.com [cached]

Earlier that morning, at 7:45 and in a different location, Patrick Zarrinkar, Ph.D., Ambit's Vice President, Technology Development will present preclinical data generated on AC220 during the New Targeted Drugs (preclinical) session.

On the evening of Sunday, December 7, a poster highlighting the clinical pharmacokinetics and effect of AC220 on FLT3 phosphorylation will be presented from 6:00 to 8:00.


Screening for a family of targets ...

www.genengnews.com [cached]

Screening for a family of targets rather than a single target is becoming more common in HTS, says Patrick Zarrinkar, Ph.D., director of molecular biology and technology development at Ambit Biosciences (www.ambitbio.com).The firm offers a new technology to screen compounds against a large panel of kinases as opposed to the traditional approach of screening compounds against a single kinase in a single assay at a given time.

The KinomeScan platform screens small molecule compounds against a panel of 235 kinases simultaneously, providing a fast, accurate, uniform, and quantitative kinase profile for each compound, claims Dr. Zarrinkar.KinomeScan turns the cross-reactivity issue of kinase inhibitors into a discovery advantage, revealing how well compounds bind not only to their intended targets, but also to mutations and unintended targets that may cause side effects or offer new uses for existing drugs, he adds.
Our proprietary technology enables kinase researchers to efficiently perform a high-content and high-throughput screening assay under standardized conditions.We are currently working on expanding our technology to include more kinases in our assay panel, says Dr. Zarrinkar.


C21 BioVentures Conference

www.techvision.com [cached]

Patrick ZarrinkarHead of Molecular Biology and Technology Development

...
Dr. Zarrinkar is Head of Molecular Biology and Technology Development at Ambit Biosciences in San Diego, California.He has been with the company since October, 2000.Ambit is a small molecule discovery company that uses its proprietary kinase profiling technology to accelerate and guide small molecule kinase inhibitor development.
Prior to joining Ambit, Dr. Zarrinkar was a Staff Scientist at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego (1999-2000).At GNF, he worked in collaboration with Affymetrix Inc. to develop high throughput methods for global gene expression profiling.Dr. Zarrinkar received his Ph.D. in 1996 from the Department of Chemistry at the Massachusetts Institute of Technology.He was a postdoctoral fellow in the Center for Genetic and Cellular Therapies of the Department of Surgery at Duke University Medical Center from 1996 to 1999.


Patrick Zarrinkar, Ph.D., ...

www.lifesciencesinfo.com [cached]

Patrick Zarrinkar, Ph.D., Sr. Director, Technology Development & Alliance Management, Ambit Biosciences

...
Patrick Zarrinkar, Ph.D., Sr. Director, Technology Development & Alliance Management, Ambit Biosciences

Similar Profiles

Other People with this Name

Other people with the name Zarrinkar

Mona Zarrinkar
State Street Corporation

Patrick Zarrinkar
Pfizer Inc

Patrick Zarrinkar

Patrick Zarrinkar
Blueprint Medicines Corp

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory